World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
114
Citations
42359
World Ranking
4787
National Ranking
2595

Research.com Recognitions

  • 2006 - Distinguished Scientist Award, American Heart Association
  • 2000 - William Beaumont Prize, American Gastroenterological Association (AGA)
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Donald Small is a researcher affiliated with Johns Hopkins University in the United States, specializing in medicine with a focus on hematology, molecular biology, and cancer research. Their work primarily addresses acute myeloid leukemia and related fields involving protein degradation, cancer genomics, and immune regulation.

Their research spans multiple aspects of leukemia treatments and diagnostics, with a significant emphasis on acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The main topics covered in their publications include:

  • Acute Myeloid Leukemia Research
  • Protein Degradation and Inhibitors
  • Chronic Myeloid Leukemia Treatments
  • Cancer Genomics and Diagnostics
  • Chronic Lymphocytic Leukemia Research
  • Acute Lymphoblastic Leukemia Research
  • Phagocytosis and Immune Regulation

Frequent co-authors of Donald Small include:

  • Li Li
  • Bao Nguyen
  • Ruiqi Zhu
  • Tessa Seale
  • Mark J. Levis

Their work has been published in a range of scientific journals, with notable venues as:

  • Blood
  • Leukemia
  • Cancer Research
  • Signal Transduction and Targeted Therapy
  • Blood Advances

Some recent papers published by Donald Small include:

  • FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation, 2021, Signal Transduction and Targeted Therapy
  • FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631, 2021, Leukemia
  • Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis, 2021, Blood Advances
  • A Method for Overcoming Plasma Protein Inhibition of Tyrosine Kinase Inhibitors, 2021, Blood Cancer Discovery
  • A Potent Small Molecule Inhibitor of FLT3, PHI-101 Overcomes Resistance in Acute Myeloid Leukemia: Efficacy and PK/PD Profile in Phase 1 First in Human Study, 2022, Blood

Donald Small's research is concentrated on treatment resistance, molecular mechanisms of leukemia, and therapeutic strategies involving tyrosine kinase inhibitors and other targeted agents. Their studies often explore synergy effects in drug combinations and the genetic mutations defining disease subtypes.

Throughout their career, Donald Small has been recognized by several awards and memberships, which include:

  • Distinguished Scientist Award, American Heart Association, 2006
  • William Beaumont Prize, American Gastroenterological Association (AGA), 2000
  • Member of the Association of American Physicians

Best Publications

  • The physicochemical basis of cholesterol gallstone formation in man

    William H. Admirand;Donald M. Small

  • Nature of the Thermal pretransition of synthetic phospholipids: dimyristolyl- and dipalmitoyllecithin.

    Martin J. Janiak;Donald M. Small;G. Graham Shipley

  • Lipid Digestion and Absorption

    M C Carey;D M Small;C M Bliss

  • The physical chemistry of cholesterol solubility in bile. Relationship to gallstone formation and dissolution in man.

    M C Carey;D M Small

  • Temperature and compositional dependence of the structure of hydrated dimyristoyl lecithin.

    M J Janiak;D M Small;G G Shipley

  • Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

    B. Douglas Smith;Mark Levis;Mark Levis;Miloslav Beran;Miloslav Beran;Francis Giles;Francis Giles

  • Detergent Properties of Bile Salts: Correlation with Physiological Function

    and A F Hofmann;D M Small

  • Micelle Formation by Bile Salts: Physical-Chemical and Thermodynamic Considerations

    Martin C. Carey;Donald M. Small

  • STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells

    D Small;M Levenstein;E Kim;C Carow

  • Phase equilibria and structure of dry and hydrated egg lecithin

    Donald M. Small

  • Plasma high-density lipoproteins.

    Alan R. Tall;Donald M. Small

  • A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

    Mark Levis;Jeffrey Allebach;Kam-Fai Tse;Rui Zheng

  • FLT3: ITDoes matter in leukemia.

    M Levis;D Small

  • Ionization and phase behavior of fatty acids in water: application of the Gibbs phase rule

    David P. Cistola;James A. Hamilton;David Jackson;Donald M. Small

  • The characteristics of mixed micellar solutions with particular reference to bile

    Martin C. Carey;Donald M. Small

  • The physical chemistry of lipids : from alkanes to phospholipids

    Donald M. Small

  • The effects of glyceride structure on absorption and metabolism.

    D M Small

  • George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry.

    D M Small

  • Structure and interactions of lipids in human plasma low density lipoproteins.

    R J Deckelbaum;G G Shipley;D M Small

  • A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

    Steven Knapper;Alan K Burnett;Timothy Littlewood;W Jonathan Kell

Frequent Co-Authors

Mark J. Levis
Mark J. Levis Johns Hopkins University
James A. Hamilton
James A. Hamilton Boston University
G. Graham Shipley
G. Graham Shipley Boston University
Curt I. Civin
Curt I. Civin University of Maryland, Baltimore
David L. Huso
David L. Huso Johns Hopkins University
Alan R. Tall
Alan R. Tall Columbia University
Martin C. Carey
Martin C. Carey Brigham and Women's Hospital
B. Douglas Smith
B. Douglas Smith Johns Hopkins University
Michael J. Borowitz
Michael J. Borowitz Johns Hopkins University
Richard J. Deckelbaum
Richard J. Deckelbaum Columbia University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in alternative routes to a medical career, online degrees offer flexible opportunities to advance your education and professional prospects, even while working or managing family commitments.

Nurses looking to take on more advanced roles may want to explore online dnp programs. These programs make it more accessible for registered nurses to earn a Doctor of Nursing Practice degree, unlocking higher salaries and leadership positions. If you're at the beginning of your nursing journey, fast track lpn programs online enable you to quickly enter the healthcare workforce with essential skills.

With the increased demand for mental health professionals, nurses can also consider psych np programs to become psychiatric nurse practitioners. This pathway is ideal for those wanting to specialize in mental health care and support diverse patient populations.

Finally, for those interested in management or administration, pursuing a health care administration degree online can help you transition into leadership roles in hospitals or medical organizations. Each of these online programs provides unique advantages, offering flexibility and accessibility for aspiring healthcare professionals.

Best Scientists Citing Donald Small

Trending Scientists

Recently Published Articles